Αρχική World News Machine Learning-Based Model Shows Promise for Indicating Response to Immune Checkpoint Inhibition

Machine Learning-Based Model Shows Promise for Indicating Response to Immune Checkpoint Inhibition

A machine learning-based model using clinical and patient-reported data from patients with various cancers may be an accurate tool for prediction of the objective response rate (ORR) following treatment with immune checkpoint inhibitors (ICIs), according to findings presented at the ESMO Immuno-Oncology Virtual Congress 2020, held from 9 to 12 December 2020.

In this study (NCT3928938) Sanna Iivanainen of the Oncology and Radiotherapy Department, Oulu University Hospital in Oulu, Finland and colleagues investigated whether a machine learning model that combines clinical and patient-reported data could be used to predict patient response following treatment with ICI.

The investigators constructed a machine learning-based prediction model for the ORR using data of 31 patients receiving ICI therapies for various advanced cancers. Of the prospectively collected data sources used as inputs for the model, 63 were clinician-assessed treatment responses, and others included reported immune-related adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) and laboratory measurements consisting of 9 values. Patient-reported symptom data including 18 monitored symptoms was collected using the Kaiku Health digital platform. The model also included the time from treatment initiation, as well as the patients’ age and sex. The laboratory values and patient-reported symptoms, were expressed as changes from baseline, and were linked to the treatment responses.

The prediction model for ORR was built using gradient a boosting technique (XGBoost). Prediction performance for unseen samples was evaluated using leave-one-out cross-validation (LOOCV), which trained and tested 63 models, each time iteratively leaving one sample out as a test set. The LOOCV prediction performance was evaluated with accuracy measures including the area under curve (AUC), F1 score, and Matthew’s correlation coefficient (MCC).

The model provided an ORR prediction following ICI therapy

The machine learning-based model was able to predict the ORR in patients undergoing ICI treatment for various cancers using XGBoost LOOCV performance with 75% accuracy, AUC 0.71, F1 score  = 0.58, and 0.40 MCC.

Machine-Learning-Based-Model-Shows-Promise-for-Indicating-Response-to-Immune-Checkpoint-Inhibition

Non-zero feature importances of ORR prediction model trained with all available samples. The displayed importances depict the relative average improvement in prediction accuracy across all 100 trees in the model where a certain feature is utilised. The importances should be considered as relative to each other.

© Sanna Iivanainen.

Conclusions

According to the authors, this study demonstrated that it is possible to predict the ORR for patients undergoing ICI therapies with a machine learning model combining clinical, routine laboratory, and patient-reported data even with a limited size cohort.

They concluded that these promising results indicate that machine learning-based approaches in treatment response prediction warrant further investigation and validation with a larger dataset.

No external funding was disclosed for this study.

Reference

38P – Iivanainen S, Ekstrom J, Virtanen H, et al. Predicting objective response rate (ORR) in immune checkpoint inhibitor (ICI) therapies with machine learning (ML) by combining clinical and patient-reported data. ESMO Immuno-Oncology Virtual Congress 2020 (9-12 December).

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Despite Proven Safety of HPV Vaccines, More Parents Have Concerns

October 22, 2021, by NCI Staff Credit: National Cancer Institute Despite more than 15 years of consistent evidence that HPV vaccines are safe and effective, a...

FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

On 15 October 2021, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy...

Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities

Suzette Simon lost her mother to breast cancer. In 2020, she learned that she had the disease, as well. Realizing how much harder breast...

Why Wearing Comfortable Clothes During Cancer Treatment Matters

Voices on Cancer is an award-winning Cancer.Net Blog series where advocates share their stories and the lessons they have learned about being a cancer advocate. Cindy Trice is...

Breast cancer surgery: ‘I’m proud of the tattoos inked across my chest’

Wendy had a double mastectomy in 2017 and remained flat. “When the consultant told me, I remember crying and saying that I have 2 young...

EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment of Waldenström’s Macroglobulinaemia

On 16 September 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of...